1. Launch Status
2004 Oct… Dec 2005 Jan… Mar Apr May Jun Jul Aug Sept… Dec 2006
UK Netherlands Norway France Italy Japan
Germany Sweden Spain
Mexico Finland
• Carefully monitoring launches and rapidly sharing
learnings across geographies
• Japan will launch with hypertension indication

2. EU Launches Leverage US Learnings
Reach and 19 CHRs (80% time on 100 PHRs* 2 Hospital
frequency Inspra) – Inspra 2 nd position teams
– Experienced in 32 IHRs (covering > – Inspra 1st
cardiology/hospitals 300 bed hospitals) position
– 9 HF nurses – Inspra 1st position
Early and HF nurses preparing Extensive AB plan Already on
broad hospital patient care pathways and (1000 studies w/5000 nearly all
access identifying advocates on patients – all in- hospital
D&T committee hospital starts) formularies
Urgency to Timing allowed addition of Could not be Launched with
treat 30-day data, but it is not incorporated at launch new concept
hospitalized the focus – updating the because no publication
patient focus in next wave available – updating
materials in next wave
* Significant distraction due to Lipitor access issues.

3. Current Status
• Communication platform refined to
establish risk and urgency, focus on
hospital initiation
• Limited US FF reach and frequency
continues to be a challenge
• US Launch learnings incorporated into
EU Launch plans
– Representatives in Ex-US markets selling
Inspra in 1st and 2nd position
– France doing extensive pre-launch
campaign to get on hospital formularies
and protocols
• Spironolactone comparison is a key issue
during details (cost, MOA)
• Pricing continues to be an issue in EU